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A B S T R A C T
Hypoxic blood-brain barrier (BBB) dysfunction is a common feature of CNS diseases however mechanisms un-
derlying barrier disturbance are still largely unknown. This study investigated the role of transforming growth
factor β (TGFβ), a cytokine known to induce expression of the proprotein convertase Furin, in hypoxia-mediated
barrier compromise. We show that exposure of brain endothelial cells (ECs) to hypoxia (1% O2) rapidly sti-
mulates their migration. Additional exogenous TGFβ (0.4 nM) exposure potentiated this eﬀect and increased
Furin expression in a TGFβ type I receptor activin-like kinase 5 (ALK5) - dependent manner (prevented by 10 μM
SB431542). Furin inhibition prevented hypoxia-induced EC migration and blocked TGFβ-induced potentiation
suggesting existence of a feedback loop. TGFβ and Furin were also critical for hypoxia-induced BBB dysfunction.
TGFβ treatment aggravated hypoxia-induced BBB permeability but ALK5 or Furin blockade reversed injury-
induced permeability changes. Thus during insult Furin compromises endothelial integrity by mediating the
eﬀects of TGFβ. Targeting the Furin or ALK5 pathway may oﬀer novel therapeutic strategies for improving BBB
stability and CNS function during disease.
1. Introduction
A stable well-functioning blood-brain barrier (BBB) is crucial to
maintain and control cerebral homeostasis as well as ensure proper
neuronal function. The BBB is formed by specialized brain endothelial
cells (EC) that limit paracellular movement of substances to and from
the brain parenchyma by their tight junctions (TJ) [1,2]. Pericytes and
perivascular astrocytes present at the vascular wall also contribute to
barrier maintenance [3]. BBB dysfunction allows the inﬂux of damaging
molecules, leading to neuronal cell loss and consequently cognitive
decline and CNS disease [4].
Hypoxia is a key stress factor that induces BBB disturbance and
increases vessel permeability through a variety of diﬀerent mechanisms
including EC cytoskeletal reorganization, TJ protein delocalization and
altered molecular pathway signaling [5,6]. Hypoxic insults induce the
expression of transforming growth factor-β1 [7] and during CNS injury
and disease levels of bioactive TGF-β1 increase [7–9]. Transforming
growth factor betas (TGF-βs) are known multifunctional growth factors
that participate in regulation of key events during development, dis-
ease, and tissue repair. In the brain TGF-β1, 2 and 3 are broadly ex-
pressed with TGF-β1 widely recognized as an injury-related cytokine.
Canonical TGF-β signaling is initiated by ligand binding to a high-af-
ﬁnity transmembrane TGF-β type II receptor (TGFβRII) that recruits
and phosphorylates the type 1 receptors activin-like kinase 1 and 5
(ALK1, ALK5). Subsequent phosphorylation of the downstream eﬀector
proteins Smad2 and Smad3 via ALK5 or Smad 1, 5 and 8 via ALK1
causes formation of a heteromeric complex with Smad4, nuclear
translocation and transcriptional regulation [10]. At the level of the
endothelium TGF-β can signal through both ALK1 and ALK5 and induce
diﬀerent molecular pathways depending on context or dosage [11].
The pleiotropic cytokine TGFβ-1 (henceforth referred to as TGFβ) is
involved in many crucial physiological processes such as cell growth,
cell diﬀerentiation, migration and apoptosis [11] depending on the cell
type. For example, whilst the growth factor induced vessel formation in
bovine capillary endothelial cells (BCEC), others showed it promoted
apoptosis in BCECs and HUVECs and could inhibit the proliferation of
bovine heart ECs [12]. Targeted deletion of various TGFβ signaling
pathway components in mice led to embryonic lethality due to im-
paired vascular development with leaky vessels [13] and/or angio-
genesis defects [14]. In correlation dysfunctional TGFβ signaling has
been observed in several pathological conditions linked to vascular
compromise such as cancer [15], ﬁbrotic disease [16] and athero-
sclerosis [17]. The TGFβ pathway is clearly a major regulator of blood
vessel characteristics.
TGFβ has been shown to induce expression of the proprotein con-
vertase Furin in synovial cells and ﬁbroblasts [18]. Furin, a calcium-
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dependent ubiquitously expressed cellular endoprotease [19], is known
to process several protein precursors associated with vascular re-
modeling and cell movement such as vascular endothelial growth factor
C (VEGF-C) [20], platelet derived growth factor (PDGF-BB) [21] and
membrane-type 1 matrix metalloprotease 1 (MT1-MMP) [22]. Very
recently it was demonstrated that Furin deﬁciency in myeloid cells at-
tenuated revascularization after oxygen-induced retinopathy [23].
Overall a crucial role for Furin in modulating various vascular en-
dothelia possibly via existence of feedback loops between the enzyme
and its substrates has been suggested. In this regard it is important to
note that a number of studies using cells of other origin have also
convincingly shown Furin to be a TGFβ converting enzyme [24–26].
Whether signaling between these two factors occurs at the BBB and/or
modulates barrier dysfunction is unknown.
The aim of this study was to investigate the eﬀect of TGFβ on barrier
stability during injury and the potential involvement of Furin in the
process. We demonstrate that TGFβ potentiates hypoxia-induced brain
EC migration and BBB permeability, and that Furin plays a key role in
mediating these eﬀects.
2. Materials and methods
2.1. Cell culture
The rat brain endothelial cell line RBE4 [27] was used for experi-
ments at passages between 36 and 49 at 80–90% conﬂuency. Cells were
maintained on rat-tail collagen coated petri dishes in 1:1 αMEM/Ham's
F-10 medium mixture supplemented with 10% FBS, 300 μg/mL Ge-
neticin purchased from Gibco® (Thermo Fisher Scientiﬁc, MA, USA) and
1 ng/mL basic ﬁbroblast growth factor (PeproTech, NJ, USA). Rat-tail
collagen was isolated as previously described [28] and diluted to
250 μg/mL in 70% Ethanol.
2.2. Primary endothelial cell isolation
Primary rat brain endothelial cells (primary ECs) were isolated from
8 to 10 week old male Wistar rats according to Coisne et al. [29], with
slight modiﬁcations. Cortices were homogenized after removal of me-
ninges in a Dounce homogenizer. Microvessels were isolated by adding
an equal volume of 30% dextran solution to the homogenate and sub-
sequent centrifugation at 3000g for 25min at 4 °C, then ﬁltered through
a 60 μm nylon mesh to remove larger vessels. After digestion in HBSS
buﬀer supplemented with 10mM HEPES, 0.1% BSA, 2mg/mL col-
lagenase-dispase, 10 μg/mL DNase I and 147 ng/mL TLCK, for 45min
at 37 °C, microvessels were re-suspended in endothelial media (DMEM
Glutamax II supplemented with 10% calf serum, BME amino acids,
vitamin solution, 2mM L-glutamine, 1 ng/mL bFGF, 59 μg/mL genta-
mycin sulfate). After plating on collagen IV coated culture dishes
pericyte contamination was prevented by exposing cultures to 3 μg/mL
puromycin-containing media for 24 h. Cells were used in experiments
on day 5 without passaging.
2.3. Hypoxic and substance exposures
Hypoxic exposures were performed in a hypoxic glove box chamber
at 37 °C, 5% CO2 and 1% O2 (InVivO2 400, Ruskinn Technologies,
Pencoed UK). An internal O2 sensor monitored O2 concentrations con-
stantly. The following substances were added exogenously to the cell
media: 0.4 nM human TGFβ-1 (PeproTech) dissolved in 10mM citric
acid, 10 μM ALK5 inhibitor SB431542 (Tocris, Bristol, UK) in DMSO,
20 μM Naphthoﬂuorescein (Furin inhibitor, Santa Cruz, TX, USA) in
DMSO, 20 μM Decanoyl-Arg-Val-Lys-Arg-chloromethylketon (CMK,
Furin inhibitor, Santa Cruz) in H2O. Cells were pretreated with in-
hibitors for 1 h prior to hypoxic and TGFβ exposures.
2.4. Cell viability
Viability of conﬂuent cells was assessed using MTT (3-(4,5-di-
methylthiazol-2-yl)-2,5-diphenyltetrazolium bromide). MTT solution
(Sigma-Aldrich, MO, USA) was added to the media (ﬁnal concentration
0.5 mg/mL) and incubated for 1 h at 37 °C. The media was removed and
formazan crystals dissolved in DMSO. Optical density was measured at
570 nm on a spectrophotometer (Thermo Labsystems, Multiskan RC
Model 351) with reference ﬁlter at 670 nm.
2.5. Cell migration
RBE4 cells were grown in 6-well plates and a scratch was introduced
vertically with a 200 μL pipette tip. Three pictures were taken per well
before and after the exposures with an inverted microscope coupled to
an 8-bit CCD camera (Axiocam HR, Carl Zeiss, Switzerland). Image
analysis using ImageJ software (NIH, USA) was used to determine
scratch width. Mean migration (μm/h) was calculated by evaluating the
diﬀerence in gap size before and after the exposure.
2.6. Permeability assay
ECs were grown to conﬂuency on 0.4 μm Transwells (Corning
Incorporated, NY, USA). After exposures fresh medium containing
1mg/mL Lucifer yellow CH, lithium salt (Life technologies, OR, USA)
was added to the upper compartment. At 9, 15, 30, 45 and 60min
aliquots were taken from the bottom compartment and tracer ﬂux was
determined with a ﬂuorescence plate reader (FLx800, Biotek
Instruments, Winooski, VT). A clearance slope established from the
measurements obtained at the diﬀerent time points was used to cal-
culate the permeability coeﬃcient (Pe) [30].
2.7. Western blotting
Cells were lysed in whole cell lysis buﬀer (50mM Tris, 150mM
NaCl, 1% Triton X-100, 1% NP-40) supplemented with protease in-
hibitor cocktail (Calbiochem, Darmstadt, Germany), 1 mM sodium or-
thovanadate and 0.5 mM phenylmethansulfonyl ﬂuoride. Protein con-
centrations were determined with a Pierce BCA protein assay (Thermo
Fischer Scientiﬁc). Proteins (50 μg) were separated by SDS-PAGE then
transferred to nitrocellulose membranes and blocked with 5% non-fat
dried milk or 5% BSA in TBS. After incubation in primary antibodies
over night at 4 °C membranes were washed then incubated with the
corresponding HRP-conjugated secondary antibody. Bands were vi-
sualized with a luminescent image analyzer (Fujiﬁlm, LAS-3000,
Switzerland) and quantiﬁcation was performed with ImageJ software
(NIH, USA) using β-actin as loading control. The following antibodies
were used: anti-Furin (SC-20801, Santa Cruz), anti–HIF–1α (NB100-479
W-1, NovusBio), anti-pSmad2 (138D4, Cell Signaling), anti-Smad2
(D43B4, Cell Signaling), anti-Smad1/5 (D5B10, Cell Signaling), anti-
Smad1 (D59D7, Cell Signaling) and β-actin (A5441, Sigma-Aldrich).
2.8. Quantitative RT-PCR
RNA was isolated from cells using TRIzol® reagent (Thermo Fisher).
Total RNA (1 μg per sample) was reverse transcribed with oligo-dT
primers using the ImProm-II ReverseTranscriptase kit (Promega,
Switzerland) according to the manufacturers protocol. Real-time
quantitative PCR (qPCR) was performed with an ABI 7500 Fast Real-
Time PCR System using Power SYBR® Green Master Mix (Applied
Biosystems, Switzerland). The following primers were employed: Furin
5′-CAG AAG CAT GGC TTC CAC AAC-3′ and 5′-TGT CAC TGC TCT GTG
CCA GAA-3′ and β-actin 5′-CTG GCT CCT AGC ACC ATG AAG-3′ and 5′-
GCC ACC GAT CCA CAC AGA GT-3’. Serial cDNA dilution series were
used to establish optimal primer conditions resulting in>90% eﬃ-
ciency. To exclude primer dimer and oﬀ-target ampliﬁcations melting
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curves were performed and conﬁrmed by gel electrophoresis. Data was
normalized to β-actin and fold changes calculated using the ΔΔCt
method.
2.9. Statistical analysis
Statistical Analyses were performed with Prism GraphPad 6. Results
are shown as mean values ± standard deviation with a minimum of 3
independent experiments. Statistical signiﬁcance was determined by
two-way ANOVA when comparing more than two diﬀerent groups with
diﬀerent exposures or unpaired Student's t-test with homoscedasticity.
A p value less than 0.05 was considered signiﬁcant.
3. Results
3.1. TGFβ promotes EC migration
Till now the role of TGFβ signaling has been mainly studied in
peripheral ECs whereas its eﬀects on the brain endothelium remain
largely debated. In the ﬁrst instance, we aimed to establish how in-
creased TGFβ levels impact brain EC quiescence during hypoxic injury
using a classic scratch migration assay and the rat brain microvascular
endothelial (RBE4) cell line. Notably, our studies have shown this cell
line exhibits the same responses as primary cells but with increased
sensitivity to oxygen deprivation [6]. Scratch assays were performed
during 6 h normoxic and hypoxic exposure with exogenous TGFβ and
ALK5 inhibitor treatment (Fig. 1A&B). Quantiﬁcation showed no sig-
niﬁcant changes under normoxic conditions with any of the treatments
(Fig. 1C). In contrast hypoxia signiﬁcantly increased EC migration and
TGFβ potentiated this eﬀect. Notably, both hypoxic and TGFβ-mediated
migration were completely blocked when ECs were pretreated with the
TGFβ receptor I inhibitor (SB431542). Thus TGFβ potentiates hypoxia-
mediated cell migration via a TGFβR1 dependent mechanism.
3.2. Hypoxia and TGFβ modulate furin protein and expression and
activation
Since existence of a feedback loop between TGFβ and Furin has
been implicated in various other (non-vascular) cells [24–26], we asked
if a similar mechanism could underlie the movement we observed. As
Furin mRNA levels were unaﬀected in our treatment conditions (Supp.
Fig. 1) we evaluated whether Furin activation correlated with the
TGFβ-induced migratory eﬀects. Hypoxic HIF-1α stabilisation con-
ﬁrmed the endogenous endothelial cell response was as expected and
unaﬀected by TGFβ treatment (Fig. 2A). Corresponding Furin im-
munoblots showed two prominent bands corresponding to the inactive
precursor form at 96 kDa and the mature active form at 90 kDa
(Fig. 2A). Quantitative analysis of the individual bands revealed a sig-
niﬁcant decrease of the Furin precursor under hypoxia. Notably, TGFβ
had no impact on normoxic precursor levels but induced hypoxic pre-
cursor levels by 50% to reach the baseline normoxic levels (Fig. 2B).
Mature Furin levels remained unchanged by hypoxia compared to the
normoxic baseline (Fig. 2C) but signiﬁcantly increased during hypoxic
TGFβ exposure, with a trend to also increase in normoxia. This data
suggests that during stress (hypoxic) conditions high TGFβ levels might
potentiate EC Furin activation by elevating precursor levels and indu-
cing protein maturation.
3.3. Furin activation is dependent on ALK5 signaling
In ECs, canonical binding of TGFβ to ALK5 causes downstream ac-
tivation and phosphorylation of Smad2 resulting in stimulation of an-
giogenesis [31], whereas signaling via ALK1 induces phosphorylation of
Smad1, 5 and 8 and subsequent endothelial quiescence [32]. Exposure
of brain ECs to TGFβ but not hypoxia increased phosphorylated Smad2
levels whereas the opposite eﬀect was observed on phospho-Smad1/5
levels (Supp. Fig. 2&3). In line with suppressing cell migration (Fig. 1),
ALK5 blockade also prevented TGFβ-mediated Smad2 phosphorylation
but not the hypoxia-induced Smad1/5 activation. As Furin levels were
also strongly potentiated by both hypoxia and TGFβ (Fig. 2) we asked if
ALK5 blockade would suppress these eﬀects (Fig. 3). Indeed im-
munoblotting showed SB431542 abrogated expression of the Furin
precursor and mature forms by more than 50% during hypoxia and
TGFβ exposure (Fig. 3). Interestingly, this pattern was also observed
during normoxia (Supp. Fig. 4) suggesting Furin activity is highly de-
pendent on ALK5 activation in both injury and physiological condi-
tions.
3.4. Furin inhibition prevents EC migration
We next evaluated if Furin is the mediator of hypoxia- and TGFβ-
induced EC migration. A scratch assay was performed over 6 h hypoxia
Fig. 1. TGFβ promotes EC migration
Representative micrographs of scratched conﬂuent RBE4 monolayers exposed to 0.4 nM TGFβ, the ALK5 inhibitor SB431542 (10 μM) or a combination of both prior
to Nx (A) or Hx (B) incubation for 6 h. Scale bar = 100 μm. Images were quantiﬁed and mean migration in μm/h is presented (C). Mean ± SD (n = 3), 2way
ANOVA, **p < 0.01 compared to Nx UNT, #p < 0.05 ##p < 0.01 ###p < 0.001 compared to Hx TGFβ.
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Fig. 2. Both hypoxia and TGFβ modulate Furin.
(A) Representative Western blot of Furin precursor (96 KDa) and mature (90 KDa) forms and HIF-1α stabilisation at 6 h hypoxia with and without TGFβ treatment.
Blot quantiﬁcation and graphical representation shows changes of the Furin forms under hypoxia and TGFβ treatment (B&C). β-actin was used as loading control.
Data are expressed as mean ± SD of at least n = 3 independent experiments. Students t-test and 2way ANOVA, *p < 0.05 compared to Nx UNT, §p < 0.05
compared to Hx UNT.
Fig. 3. Furin activation is dependent on TGFβ receptor-1 ALK5 signaling.
(A) Representative blot showing Furin protein expression after TGFβ or SB431542 treatment. Quantitative graphs show comparative levels of both precursor (B) and
mature (C) Furin. Mean ± SD (n= 3), Students t-test, §p < 0.05, §§p < 0.01 compared to Hx UNT, ###p < 0.001 to Hx TGFβ.
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as previously in the presence and absence of TGFβ and the Furin in-
hibitors Naphthoﬂuorescein [33] and CMK. Clear diﬀerences were ap-
parent after visual inspection of the samples (Fig. 4A). Quantiﬁcation
showed hypoxia-induced cell migration was signiﬁcantly potentiated
when combined with exogenous TGFβ as expected however treating
cells with Furin inhibitors completely abrogated this response even in
the presence of TGFβ (Fig. 4B). Notably, both inhibitors also blocked
normoxic EC migration by up to 60% (Supp. Fig. 5). These observations
highlight that TGFβ-induced EC migration is mediated by Furin and
again underline an important physiological role for Furin.
3.5. TGFβ potentiates hypoxia-mediated EC permeability
To understand whether injury-increased TGFβ levels contribute to
altered barrier integrity we performed permeability assays on primary
microvascular ECs isolated from adult rat brain and RBE4 (data not
shown) in presence and absence of exogenous TGFβ (Fig. 5).
Experiments were performed for 24 h (Figs. 5A) and 48 h (Fig. 5B)
under normoxic and hypoxic conditions. Hypoxia signiﬁcantly in-
creased permeability of EC monolayers as frequently observed in many
studies including our own [3]. Exposure to TGFβ further potentiated
hypoxia-induced barrier dysfunction although no eﬀects were observed
under normoxia (Fig. 5A). Pretreatment with SB431542 completely
abrogated TGFβ and hypoxic driven eﬀects to baseline normoxic levels.
Indeed at both time points a similar outcome was seen although the
eﬀects at 48 h were clearly more enhanced (Fig. 5A&B). Thus sustained
injury-induced activation of the endothelial TGFβ-ALK5 pathway cul-
minates in barrier disturbance.
3.6. Furin inhibition prevents hypoxia-induced barrier permeability
Finally, due to the observed feedback between the proteins, we in-
vestigated if Furin inhibition would also suppress the barrier changes
induced by hypoxic and/or TGFβ exposure. Again we employed the
Fig. 4. Furin inhibition prevents EC migration
Representative micrographs of scratched RBE4 monolayers incubated with TGFβ, the Furin inhibitors Naphthoﬂuorescein (Naph, 20 μM) or CMK (20 μM) or a
combination of both prior to Hx exposure for 6 h (A). Scale bar = 100 μm. Quantiﬁed data (B) shows changes in EC migration under all conditions. Mean ± SD of at
least n = 3 independent experiments. 2way ANOVA, ***p < 0.001 compared to Nx UNT, ###p < 0.01, ##p < 0.01 compared to Hx TGFβ, §§p < 0.01 to Hx
UNT.
Fig. 5. TGFβ potentiates hypoxia-mediated EC permeability via ALK5
Permeability assay was performed on primary rat endothelial cells grown to conﬂuency on transwells then exposed to 0.4 nM TGFβ or 10 μM SB431542 during 24 h
(A) and 48 h (B) hypoxia. Dashed line indicates normoxic baseline measurements. 2way ANOVA and Students t-test, §§p < 0.01, §§§p < 0.001 compared to Hx
CTRL, ##p < 0.01 compared to Hx TGFβ treatment, Students t-test.
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transwell permeability assay using primary rat ECs (Fig. 6A) and RBE4
(data not shown). Blocking Furin activation with CMK was highly ef-
ﬁcient at preventing hypoxia-mediated barrier disruption after 48 h.
Similar to observations in the migration assay, the CMK inhibitor re-
sulted in a tighter monolayer than observed under normoxic conditions
(Fig. 6A). Surprisingly however the combination of CMK and exogenous
TGFβ dramatically increased EC barrier permeability by more than 5
fold. This led us to use MTT assays to assess if the observed permeability
changes were due to compromised cell viability. Data showed that
when combined with hypoxia TGFβ treatment already compromised
cell function up to 20%. Whilst CMK alone had no eﬀect, the combi-
nation treatment reduced mitochondrial activity by 50% (Fig. 6B). Thus
Furin blockade in the presence of elevated TGFβ reduces cell viability
and strongly impairs BBB functionality.
4. Discussion
Maintaining BBB integrity is crucial for CNS homeostasis. Hypoxia
and ischemia are well known to compromise barrier stability via TJ and
extracellular matrix disruption leading to permeability changes [5].
Such alterations ultimately contribute to disease progression [4]. This
study shows that both hypoxia and exogenous TGFβ promote cell mi-
gration and barrier dysfunction via activation of the proprotein con-
vertase Furin. Blocking Furin abrogates hypoxia and TGFβ-induced
endothelial migration and permeability indicating a potential future
target for vascular-related interventions.
Stimulatory eﬀects of TGFβ on cell migration have been reported in
intestinal [34] and renal epithelial cells [35], renal microvascular EC
[36] and cancer cells [37] under normoxic conditions although high
doses of TGF-β may inhibit non-brain EC migration [11,36]. In contrast
TGFβ did not induce migration of brain ECs in normoxia but only
during hypoxic insult in correlation with a study performed on ﬁbro-
blasts [38]. Our observations thus highlight that TGFβ signaling acti-
vates angiogenic processes in brain EC only during injury conditions, a
poignant diﬀerence between peripheral cell types and brain EC.
TGFβ induces the expression of Furin, a proprotein convertase
whose up regulation consistently correlates with tumor cell activation
and invasiveness [39]. In synovial cells [40] and bovine aortic en-
dothelial cells [41] TGFβ was shown to increase Furin transcription.
Despite no clear eﬀects on mRNA levels, TGFβ treatment clearly in-
duced Furin protein levels in brain EC. Endothelial TGFβ can signal
through two diﬀerent TGFβ type I receptors, ALK5 and ALK1, which
either promote angiogenesis or induce vascular quiescence respectively
[11,32]. TGFβ signaling through ALK5 activates Smad2 and 3 whilst
signaling through ALK1 activates Smad1, 5 and 8 [8,42]. In brain ECs
diﬀerential Smad signaling was clearly stimuli-related with Smad1/5
phosphorylation being hypoxia-dependent and Smad2 activation being
TGFβ-dependent. It seems likely that a balance between activation of
ALK1 versus ALK5 determines whether ECs remain quiescent or initiate
an angiogenic response, an observation previously described by Gou-
mans et al., in 2002 [11]. In HUVEC and bovine aortic EC ALK5 majorly
contributed to angiogenic processes [31,43]. Similarly ALK5 blockade
prevented TGFβ-induced activation of Smad2 (without aﬀecting
pSmad1/5 levels) and suppressed brain EC migration in agreement with
those ﬁndings. Notably, ALK5 activation was also linked to BBB dys-
function in mouse brain endothelial cell (bEnd.3) monolayers wherein
TGFβ-induced permeability, via down regulation of the TJ protein
Claudin-5, was mediated by Smad3 [44]. Overall our data supports the
notion that suppressing ALK5 activation could be key for maintaining
BBB function. Our data also suggests Furin modulation is strongly de-
pendent on TGFβ/ALK5 signaling and mediated by Smad2 in brain EC
in line with other work [18,40,45]. Whether Smad2 directly or in-
directly regulates the eﬀects of TGFβ on Furin levels is currently under
investigation.
A curious observation from this work is that TGFβ induced mature
Furin levels under both normoxic and hypoxic conditions but enhanced
migration only occurred during hypoxia. Since Furin is a bona ﬁde HIF-
1 target [46] it seems plausible that the HIF-1 pathway could somehow
contribute to this eﬀect. HIF-1 targeted knockdown studies will further
clarify this involvement.
Convertase enzymes exist in an immature preform with a proseg-
ment still attached. Several studies have demonstrated the use of con-
vertase prosegments as inhibitors of their parent enzymes in vitro and ex
vivo [47,48]. During the maturation of Furin, the prosegment acts as a
chaperone in the auto-activation pathway as well as a potent auto-in-
hibitor [49]. Indeed profurin overexpression in vascular smooth muscle
cells decreased endogenous Furin protein levels and reduced cell pro-
liferation and migration [50]. Further hepatic overexpression of the
Furin prosegment reduced atherosclerosis progression and decreased
vascular remodeling after injury in vivo [50]. In analogy we observed
downregulation of the Furin precursor during hypoxia indicating that
potential inhibition of maturation is lifted, resulting in increased Furin
activity in line with our migration assay results. This data supports the
conclusion that increased Furin activity is ultimately responsible for
Fig. 6. Furin inhibition prevents hypoxia-induced barrier permeability Primary rat endothelial cells were grown to conﬂuency on transwells or culture dishes before
hypoxic exposure to 0.4
nM TGFβ, CMK (20 μM) or CMK combined with TGFβ for 48 h. Permeability assays (A) and MTT assays (B) were subsequently performed. Mean ± SD (n = 4),
2way ANOVA and Students t-test, **p < 0.01, ****p < 0.0001 compared to Normoxia, ##p < 0.01 to Hx TGFβ, §§p < 0.01, §§§p < 0.001 to Hx UNT.
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hypoxic EC migration especially since Furin inhibition not only pre-
vented hypoxic EC migration but also abrogated TGFβ-induced eﬀects.
In agreement Furin inhibition also attenuated TGFβ-enhanced migra-
tion of cardiac ﬁbroblasts [51], reduced invasiveness/migration and
tumorigenicity of human cancer cells in vivo [52] and in vitro [47].
Hence similar mechanisms underlie brain EC migration and likely
contribute to increased barrier permeability during injury conditions.
Although not elucidated here, a possible mechanism of Furin-mediated
cell movement is likely linked to processing of matrix metalloprotei-
nases (MMPs). Synthesized as inactive propeptides, MMPs undergo
endoproteolytic cleavage to attain their active forms [53] resulting in
extracellular matrix degradation and barrier disruption [54]. Accord-
ingly hypoxia is known to increase Furin-mediated MT1-MMP proces-
sing [22,46]. Since Furin inhibition in human cancer cells and cardiac
ﬁbroblasts decreased processing and activation of MT1-MMP/MMP-2
[51,55] it is very tempting to speculate that TGFβ-induced brain EC
migration is driven by Furin-mediated activation of MMPs.
At the BBB, a TGFβ-induced migratory (activated) EC phenotype
implies barrier compromise as cytoskeletal alterations lead to a con-
sequential loss of tight junction organization. Indeed TGFβ induced
brain EC migration and permeability and aggravated injury-induced
barrier compromise via an ALK5-dependent mechanism in contrast with
a study showing that activation of ALK5 by TGFβ inhibits migration in
non-brain ECs [13]. The unique qualities of BBB ECs including lack of
fenestrations, more extensive tight junctions, and reduced pinocytic
vesicular transport is clearly signiﬁcant [6]. Although decreased via-
bility of brain EC observed during TGFβ treatment was unexpected our
data further underscores that negative EC responses to the growth
factor can be reversed by inhibiting either ALK5 or Furin activity. In-
deed blocking of either abrogated hypoxic barrier disruption agreeing
with the notion that these pathways are tightly entwined and induce a
migratory/activated phenotype. It is now very evident that Furin acti-
vation also plays an important role in injury-induced BBB disturbance.
However an intriguing and unexpected ﬁnding, given Furin inhibition
prevented short-term hypoxic and TGFβ-induced migration, was that
combined prolonged TGFβ treatment and Furin blockade caused more
disruption than TGFβ stimulus alone in correlation with dramatically
compromised viability. The reason behind this is unclear but disruptive
and negative time-dependent eﬀects of sustained TGFβ signaling at the
BBB and potential cofounding eﬀects of modulating multiple down-
stream pathways must be better understood.
Overall our data suggests both hypoxia- and TGFβ-mediated EC
permeability can be prevented by blocking Furin and/or ALK5 activa-
tion. Notably, a large source of native active TGFβ that can be released
upon diﬀerent injury stimuli in vivo lies within the perivascular cells
and/or the extracellular matrix. Thus further studies using more com-
plex BBB models such as co-culture of ECs with perivascular cells will
be needed to provide further insight into the highly complex molecular
mechanisms and cellular cross-talk that take place during injury in vivo.
In summary, controlling Furin or ALK5 activation at the BBB could oﬀer
a novel therapeutic option for improving barrier functionality and CNS
function during disease.
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